Potent inhibitors of LpxC for the treatment of Gram-negative infections.
Brown, M.F., Reilly, U., Abramite, J.A., Arcari, J.T., Oliver, R., Barham, R.A., Che, Y., Chen, J.M., Collantes, E.M., Chung, S.W., Desbonnet, C., Doty, J., Doroski, M., Engtrakul, J.J., Harris, T.M., Huband, M., Knafels, J.D., Leach, K.L., Liu, S., Marfat, A., Marra, A., McElroy, E., Melnick, M., Menard, C.A., Montgomery, J.I., Mullins, L., Noe, M.C., O'Donnell, J., Penzien, J., Plummer, M.S., Price, L.M., Shanmugasundaram, V., Thoma, C., Uccello, D.P., Warmus, J.S., Wishka, D.G.(2012) J Med Chem 55: 914-923
- PubMed: 22175825 
- DOI: https://doi.org/10.1021/jm2014748
- Primary Citation of Related Structures:  
3U1Y - PubMed Abstract: 
In this paper, we present the synthesis and SAR as well as selectivity, pharmacokinetic, and infection model data for representative analogues of a novel series of potent antibacterial LpxC inhibitors represented by hydroxamic acid.
Organizational Affiliation: 
Worldwide Medicinal Chemistry, Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States. matthew.f.brown@pfizer.com